Five years after aortic valve replacement in patients with intermediate surgical mortality risk, transcatheter aortic valve replacement (TAVR) with a self-expanding bioprosthetic valve and surgical aortic valve replacement (SAVR) had a similar composite rate of all-cause mortality or stroke, according to new trial results.